A better understanding of the drivers of the spread of malaria parasites and drug resistance
across space and time is needed. These drivers can be elucidated using genetic tools. Here, …

Drug-like compounds are most of the time denied approval and use owing to the unexpected
clinical side effects and cross-reactivity observed during clinical trials. These unexpected …

Background. In 2005, Ghana adopted artemisinin-based combination therapy (ACT) for
primary treatment of falciparum malaria. A comprehensive study of the drug-resistance–…

The Democratic Republic of the Congo (DRC) harbors 11% of global malaria cases, yet little
is known about the spatial and genetic structure of the parasite population in that country. …

Mutations in the Plasmodium falciparum K13-propeller domain have recently been shown
to be important determinants of artemisinin resistance in Southeast Asia. This study …

Background Translating genomic technologies into healthcare applications for the malaria
parasite Plasmodium falciparum has been limited by the technical and logistical difficulties of …

A major obstacle to malaria elimination is the great capacity of the parasite and vector
populations to evolve in response to malaria control interventions. The widespread use of …

Understanding genomic variation and population structure of Plasmodium falciparum across
Africa is necessary to sustain progress toward malaria elimination. Genome clustering of …

Background Human genetic factors are important determinants of malaria risk. We investigated
associations between multiple candidate polymorphisms—many related to the structure …

Artemisinin resistance (AR) emerged in South East Asia 13 years ago and the identification
of the resistance conferring molecular marker, Plasmodium falciparum Kelch 13 (Pfk13), 7 …